EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin)

Jan Tennvall, Manfred Fischer, Angelika Bischof Delaloye, Emilio Bombardieri, Lisa Bodei, Francesco Giammarile, Michael Lassmann, Wim Oyen, Boudewijn Brans

Research output: Contribution to journalArticle

Abstract

Background: In January 2004, EMEA approved 90Y-radiolabelled ibritumomab tiuxetan, Zevalin, in Europe for the treatment of adult patients with rituximab-relapsed or -refractory CD20+ follicular B-cell non-Hodgkin's lymphoma. The number of European nuclear medicine departments using Zevalin is continuously increasing, since the therapy is often considered successful. The Therapy, Oncology and Dosimetry Committees have worked together in order to define some EANM guidelines on the use of Zevalin, paying particular attention to the problems related to nuclear medicine. Purpose: The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for radio-immunotherapy. The guideline also stresses the need for close collaboration with the physician(s) treating the patient for the underlying disease.

Original languageEnglish
Pages (from-to)616-622
Number of pages7
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume34
Issue number4
DOIs
Publication statusPublished - Apr 2007

Keywords

  • Y-ibritumomab tiuxetan
  • Guidelines
  • Non-Hodgkin's lymphoma
  • Nuclear medicine
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Fingerprint Dive into the research topics of 'EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin)'. Together they form a unique fingerprint.

  • Cite this

    Tennvall, J., Fischer, M., Bischof Delaloye, A., Bombardieri, E., Bodei, L., Giammarile, F., Lassmann, M., Oyen, W., & Brans, B. (2007). EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). European Journal of Nuclear Medicine and Molecular Imaging, 34(4), 616-622. https://doi.org/10.1007/s00259-007-0372-y